Oryzon Genomics Investor Relations Material
Latest events
KOL Event
Oryzon Genomics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Oryzon Genomics S.A.
Access all reports
Oryzon Genomics S.A. is a Spain-based clinical-stage biopharmaceutical company focused on the discovery and development of epigenetic therapies. The company develops small molecule inhibitors targeting specific enzymes involved in gene expression regulation, with therapeutic programs in oncology and neurodegenerative diseases. Oryzon conducts both preclinical and clinical trials and collaborates with academic and industry partners to advance its drug candidates. The company is headquartered in Barcelona, Spain, and its shares are listed on the BME.
Key slides for Oryzon Genomics S.A.
Corporate Presentation
Oryzon Genomics S.A.
Corporate Presentation
Oryzon Genomics S.A.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ORY
Country
🇪🇸 Spain